Forte Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul A. Wagner
- Full Time Employees
- 22
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3060 Pegasus Park Drive Dallas TX United States of America 75247
- IPO Date
- Apr 13, 2017
- CIK
- 0001419041
- Website
- fortebiorx.com
- Similar Companies
- Business
- Forte Biosciences, Inc. (FBRX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and autoimmune-related diseases, including celiac disease, vitiligo, alopecia areata and graft-versus-host disease. The company's lead product candidate is FB-102, a proprietary anti-CD122 monoclonal antibody that targets key pathways in IL-2/IL-15 receptors to modulate NK cells and certain T cell subsets; FB-102 is advancing in multiple clinical programs, including a Phase 2 trial in celiac disease with topline data expected in 2026, a vitiligo trial with enrollment commenced and topline data anticipated in the first half of 2026, and an alopecia areata trial initiating in the second half of 2025 with topline data expected in 2026. In June 2025, Forte announced positive data from an FB-102 celiac disease study; in November 2024, the company completed an oversubscribed $53 million private placement financing from leading healthcare institutional investors including OrbiMed, Janus Henderson Investors and BVF Partners LP to advance FB-102 programs; and in November 2025, Forte issued inducement grants under Nasdaq listing rules and reported $93.4 million in cash and cash equivalents as of Q3 2025. Founded in 2017 and headquartered at 3060 Pegasus Park Drive, Building 6, Dallas, Texas, Forte operates in the United States within the biotechnology sector, targeting unmet needs in dermatological and inflammatory conditions with no subsidiaries or parent company relationships disclosed.
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement
Forte Biosciences: FB102 Is Becoming A Platform Story, Not A Single-Indication Bet
Forte Biosciences, Inc. (FBRX) Discusses Positive Results From FB102 Phase 1b Vitiligo Study and Mechanism of Action Transcript
Forte Biosciences shares surge after positive phase 1b vitiligo results
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study
Forte Biosciences shares surge after positive phase 1b vitiligo results
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
Forte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data Readouts
Forte Biosciences Announces Pricing of $150 Million Public Offering
Forte Biosciences Announces Proposed Public Offering
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings